ALDVI.PA Advicenne
- Market cap
- EUR 9.60M
- P/E
- 9.0x
- P/B
- 131.47x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALDVI.PA undervalued?
Graham numberThe Graham number of Advicenne cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Advicenne fundamental analysis
6 of 11 checks passedROE 2/2
ROE surpassing expectations (222.59%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.
ROA 0/2
The stock's ROA (-81.22%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
With a remarkably low PBV ratio (-1.74x), the stock offers substantial upside potential at a bargain price.
DER 2/2
The stock has a minimal amount of debt (-177%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 1/2
Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.
Net Profit Growth 1/2
This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.
Assets Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Graham Number 1/1
The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.
Dividend Growth 0/2
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Advicenne stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizur…
Full company profileAdvicenne financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Advicenne annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 268K | 806K | 1.19M | 2.00M | 2.06M | 2.69M | 2.40M | 4.46M | 4.97M | 6.01M | 11.5M |
| Gross Profit | 169K | -3.65M | -7.27M | -10.9M | 1.18M | 1.72M | 1.28M | -6.31M | -1.18M | -922K | -12.1M |
| Operating Income | -3.17M | -5.44M | -5.63M | -14.6M | -14.1M | -12.4M | -10.1M | -6.46M | -9.06M | -8.36M | 21.0M |
| EBITDA | -3.69M | -5.05M | -5.32M | -13.9M | -14.0M | -12.0M | -9.70M | -6.23M | 1.35M | -7.81M | 23.5M |
| Net Income | -3.98M | -4.65M | -4.63M | -14.2M | -14.8M | -12.4M | -11.5M | -7.03M | -6.46M | -9.53M | 18.5M |
| EPS | -0.62 | -0.77 | -0.58 | -1.66 | -1.69 | -1.32 | -1.13 | -0.67 | -0.53 | -0.72 | 1.28 |
| Balance Sheet | |||||||||||
| Total Assets | 3.26M | 38.6M | 33.2M | 22.9M | 24.0M | 18.9M | 14.3M | 12.4M | 9.51M | 7.14M | 7.55M |
| Total Liabilities | 8.41M | 5.11M | 3.54M | 6.00M | 20.7M | 18.6M | 24.9M | 24.4M | 28.6M | 33.5M | 29.2M |
| Shareholders' Equity | -5.15M | 33.5M | 29.6M | 16.9M | 3.27M | 309K | -10.5M | -12.0M | -19.1M | -26.4M | -21.6M |
| Cash & Short-term Investments | 1.58M | 36.2M | 26.2M | 14.4M | 16.8M | 12.7M | 8.32M | 5.25M | 3.25M | 1.35M | 1.55M |
| Total Debt | 3.32M | 702K | 420K | 1.45M | 13.8M | 12.5M | 18.8M | 18.3M | 18.2M | 19.0M | 21.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 67.0K | -5.80M | -10.2M | -9.48M | -11.7M | -12.5M | -9.15M | -5.99M | -762K | -3.73M | - |
| Capital Expenditure | 24.0K | 35.0K | 142K | 934K | 575K | 297K | 115K | 1.28M | 91.0K | 382K | 0.00 |
| Free Cash Flow | 43.0K | -5.84M | -10.3M | -10.4M | -12.3M | -12.8M | -9.26M | -7.27M | -853K | -4.11M | - |
| Ratios | |||||||||||
| ROE | - | -13.9% | -15.6% | -83.9% | -453.7% | -4,021.7% | - | - | - | - | - |
| ROA | -122.2% | -12.1% | -13.9% | -61.9% | -61.8% | -65.8% | -80.4% | -56.7% | -68.0% | -133.5% | 244.8% |
| Net Profit Margin | -1,485.1% | -577.3% | -388.7% | -710.2% | -720.0% | -462.1% | -478.6% | -157.7% | -130.0% | -158.7% | 160.4% |
| Debt to Equity | - | 0.02x | 0.01x | 0.09x | 4.22x | 40.58x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Advicenne dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 5.00M | 0.49 | - |
| 2021 | EUR 56.0K | 0.01 | - |
| 2020 | EUR 41.0K | 0.00 | - |
| 2019 | EUR 43.0K | 0.01 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 514:513 on Jul 2, 2025.
Who owns Advicenne
- Insiders 4.47%
- Institutions 38.49%
- Public & others 57.04%
- Shares outstanding 15.2M
- Free float 8.88M
Advicenne company profile
- Company name
- Advicenne
- Ticker
- ALDVI.PA
- ISIN
- FR0013296746
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 262 Rue du Faubourg Saint-Honore, Paris, France, 75008
- Phone
- 33 1 85 73 36 20
- Website
- advicenne.com
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Advicenne management
6- Mr. Didier LaurensGeneral Director & Chairman of the Board · born 1966
- Ms. Delphine Dumas-CivardDeputy Chief Executive Officer
- Ms. Isabelle KervellaChief Financial Officer
- Dr. Andre Ulmann M.D., Ph.D.Chief Medical Officer, Censor & Director · born 1949
- Ms. Hege HellstromChief Commercial Officer · born 1965
- Mr. Robbie McCarthyGeneral Manager of Advicenne Inc.